Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | GFER | P55789 | 2/20 | 0.70 |
| ▸ | AHR | P35869 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | TP53 | P04637 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21683033 | 0.84 | ALDH1A1 (0.57) | MAPTSMN1; SMN2RAB9ANPC1GFER | |
| SCHEMBL21683032 | 0.84 | ALDH1A1 (0.59) | MAPTSMN1; SMN2RAB9ANPC1GFER | |
| SCHEMBL21771262 | 0.83 | ALDH1A1 (0.70) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL31504222 | 0.83 | ALDH1A1 (0.70) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL31504246 | 0.83 | RAB9A (0.68) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL21771103 | 0.83 | RAB9A (0.68) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL31504234 | 0.83 | NAMPT (0.55) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL22495261 | 0.83 | NAMPT (0.55) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL22495244 | 0.82 | LMNA (0.54) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL31504183 | 0.82 | LMNA (0.54) | MAPTSMN1; SMN2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | Sanford Burnham Prebys Medical Discovery Institute | 2022-03-03 | — | — | US | disclosed |
| EP-3833352-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | University of Central Florida Research Foundation, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| WO-2020033944-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033944-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | ANXA6, ANXA1, ANTXR2 | MAPT 4522/4885SMN1; SMN2 589/4885RAB9A 2458/4885 |
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | ENY2, ANTXR2, ALAD | MAPT 3876/4885SMN1; SMN2 2909/4885RAB9A 4032/4885 |
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | MAPT 16/4885SMN1; SMN2 410/4885RAB9A 163/4885 |
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | SLC19A1, PNMT, SRM | MAPT 2629/4885SMN1; SMN2 785/4885RAB9A 3218/4885 |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | SLC19A1, PNMT, SRM | MAPT 2629/4885SMN1; SMN2 785/4885RAB9A 3218/4885 |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | SNCA, APP, BACE1 | MAPT 17/4885SMN1; SMN2 475/4885RAB9A 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.